Soleno Therapeutics (SLNO) Non Operating Income (2017 - 2026)

Soleno Therapeutics (SLNO) has 10 years of Non Operating Income data on file, last reported at $3.6 million in Q1 2026.

• On a quarterly basis, Non Operating Income rose 84.52% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $13.1 million, a 12.18% increase from a year earlier, with the FY2025 full-year figure at $11.5 million, down 2.92% from the prior year.
• Non Operating Income for Q1 2026 stood at $3.6 million, down from $3.8 million in the prior quarter.
• Over the last five years, Non Operating Income for SLNO reached as high as $3.9 million in Q3 2025 and fell as low as -$479000.0 in Q3 2023.
• Historically, Non Operating Income has averaged $1.7 million across 5 years, with a median of $2.0 million in 2025.
• On a YoY basis, Non Operating Income climbed as much as 2008.06% in 2023 and fell as far as 565.05% in 2023.
• Year by year, Non Operating Income stood at $124000.0 in 2022, then jumped by 2008.06% to $2.6 million in 2023, then climbed by 19.89% to $3.1 million in 2024, then advanced by 20.64% to $3.8 million in 2025, then retreated by 3.86% to $3.6 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $3.6 million in Q1 2026, $3.8 million in Q4 2025, and $3.9 million in Q3 2025.